NKGen Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NKGN research report →
About the company
NKGen Biotech, Inc. , a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors.
- CEO
- Paul Y. Song
- IPO
- 2021
- Employees
- 26
- HQ
- Santa Ana, CA, US
Price Chart
- Market Cap
- $7.84M
- P/E
- -0.12
- P/S
- 12.02
- P/B
- -0.03
- EV/EBITDA
- 1.57
- Div Yield
- 0.00%
- Gross Margin
- 50.00%
- Op Margin
- -1497.85%
- Net Margin
- -2157.06%
- ROE
- 55.88%
- ROIC
- 859.68%
- Revenue
- $0 · 0.00%
- Net Income
- $-44,286,000 · 46.61%
- EPS
- $-1.54 · 71.38%
- Op Income
- $-26,966,000
- FCF YoY
- 5.07%
- 52W High
- $0.77
- 52W Low
- $0.00
- 50D MA
- $0.05
- 200D MA
- $0.13
- Beta
- 0.65
- Avg Volume
- 6.80K
Get TickerSpark's AI analysis on NKGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 27, 25 | CFIC-2015 NV Family Investments, LLC | buy | 39,339,103 |
| May 27, 25 | CFIC-2015 NV Family Investments, LLC | buy | 19,669,552 |
| May 5, 25 | Song Paul Y. | buy | 41,699,449 |
| May 5, 25 | Song Paul Y. | buy | 20,849,725 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | other | 63,634 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | sell | 757,942 |
| Dec 20, 24 | Graf Acquisition Partners IV LLC | sell | 93,334 |
| Dec 2, 24 | Graf Acquisition Partners IV LLC | sell | 713,357 |
| Dec 16, 24 | Graf Acquisition Partners IV LLC | sell | 1,212,707 |
| Dec 2, 24 | Graf Acquisition Partners IV LLC | other | 97,232 |
Our NKGN coverage
Recent articles, reports, and earnings notes.
No research on NKGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NKGN report →Similar companies
Peers in the same neighborhood.